Tech Company Inital Public Offerings

ProNAi Therapeutics IPO

Headquartered in Vancouver BC, ProNAi Therapeutics completed its IPO.

Transaction Overview

Announced On
7/17/2015
Transaction Type
IPO
Amount
$137,700,000
Proceeds Purpose
We currently anticipate that we will use the net proceeds from this offering as follows: approximately $43.0 million to fund our ongoing Wolverine Phase 2 trial, our planned Brighton Phase 2 trial that we expect to initiate in mid-2015 and manufacturing activities related to these trials; approximately $40.0 million to fund other planned future Phase 2 trials related to PNT2258 and manufacturing activities related to these trials; approximately $5.0 million to support non-clinical activities and preclinical activities related to PNT2258, including activities related to its mechanism of action; and approximately $7.0 million to further develop our DNAi technology platform and broaden our pipeline of DNAi-based product candidates. The remainder of the net proceeds will be used for working capital and other general corporate purposes as well as to pay the approximately $5.5 million of cumulative accrued dividends to our Series B and Series B-1 redeemable convertible preferred stockholders

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
885 West Georgia St. 2150
Vancouver BC, V6C 3E8
Canada
Email Address
Overview
ProNAi Therapeutics, Inc. (NASDAQ: DNAI) is a biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
Profile
ProNAi Therapeutics LinkedIn Company Profile
Social Media
ProNAi Therapeutics Company Twitter Account
Company News
ProNAi Therapeutics News
Facebook
ProNAi Therapeutics on Facebook
YouTube
ProNAi Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nick Glover
  Nick Glover LinkedIn Profile  Nick Glover Twitter Account  Nick Glover News  Nick Glover on Facebook
Chief Financial Officer
Sukhi Jagpal
  Sukhi Jagpal LinkedIn Profile  Sukhi Jagpal Twitter Account  Sukhi Jagpal News  Sukhi Jagpal on Facebook
VP - Human Resources
Diane Gardiner
  Diane Gardiner LinkedIn Profile  Diane Gardiner Twitter Account  Diane Gardiner News  Diane Gardiner on Facebook
VP - Manufacturing
Simon Eastman
  Simon Eastman LinkedIn Profile  Simon Eastman Twitter Account  Simon Eastman News  Simon Eastman on Facebook
VP - Operations
Wendy Chapman
  Wendy Chapman LinkedIn Profile  Wendy Chapman Twitter Account  Wendy Chapman News  Wendy Chapman on Facebook
VP - R & D
Emma McCann
  Emma McCann LinkedIn Profile  Emma McCann Twitter Account  Emma McCann News  Emma McCann on Facebook
VP - Regulatory Affairs
Chandra Lovejoy
  Chandra Lovejoy LinkedIn Profile  Chandra Lovejoy Twitter Account  Chandra Lovejoy News  Chandra Lovejoy on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/17/2015: Readz venture capital transaction
Next: 7/17/2015: Cianna Medical venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on every notable VC transaction. All VC database entries on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary